SIREN : 503653818
DELPHARM REIMS is a French company founded 18 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in REIMS (51100), this company of category ETI shows in 2025 a revenue of 86.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 86 840 478 € | 100 345 787 € | 86 440 681 € | 71 899 153 € | 76 665 172 € | 77 749 383 € | 73 988 761 € | 75 336 245 € | 76 778 039 € | 71 461 794 € |
| Net income | 1 464 322 € | 5 857 778 € | 3 943 158 € | 2 240 345 € | 2 592 251 € | 1 340 767 € | 1 058 993 € | 3 996 852 € | 4 931 914 € | 3 539 744 € |
| EBITDA | 6 195 901 € | 13 145 103 € | 9 275 903 € | 6 322 784 € | 8 043 807 € | 6 423 989 € | 5 923 395 € | 9 435 688 € | 10 053 605 € | 10 160 931 € |
| Net margin | 1.7% | 5.8% | 4.6% | 3.1% | 3.4% | 1.7% | 1.4% | 5.3% | 6.4% | 5.0% |
In 2025, DELPHARM REIMS achieves revenue of 86.8 M€. Revenue is growing positively over 10 years (CAGR: +2.2%). Significant drop of -13% vs 2024. After deducting consumption (33.7 M€), gross margin stands at 53.1 M€, i.e. a rate of 61%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 6.2 M€, representing 7.1% of revenue. Warning negative scissor effect: despite revenue change (-13%), EBITDA varies by -53%, reducing margin by 6.0 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.5 M€, i.e. 1.7% of revenue. This profit can be retained or distributed to shareholders.
86 840 478 €
53 129 080 €
6 195 901 €
1 855 183 €
1 464 322 €
7.1%
The debt ratio (= Financial debt / Equity x 100) stands at 59%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 26%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.7 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 6.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
59.194%
26.496%
6.741%
1.656
34.4%
In 2025, the debt ratio of DELPHARM REIMS (59.19) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of DELPHARM REIMS (26.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2025, the repayment capacity of DELPHARM REIMS (1.66) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 156.23. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 14.7x. Operating income very largely covers interest expenses: high safety margin.
156.232
14.748
In 2025, the liquidity ratio of DELPHARM REIMS (156.23) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2025, the interest coverage of DELPHARM REIMS (14.8x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 18 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 113 days. Excellent situation: suppliers finance 95 days of the operating cycle (retail model). Inventory turnover is 76 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 115 days of revenue, i.e. 27.8 M€ to permanently finance. Over 2016-2025, WCR increased by +108%, requiring additional financing.
27 757 690 €
18 j
113 j
76 j
115 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 292 160€ to 897 986€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare DELPHARM REIMS with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of DELPHARM REIMS in 2025 is 86.8 M€.
Yes, DELPHARM REIMS generated a net profit of 1.5 M€ in 2025.
The headquarters of DELPHARM REIMS is located in REIMS (51100), in the department Marne.
The tax return of DELPHARM REIMS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
DELPHARM REIMS operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.